Biomarkers of Liver Injury for Hepatitis Clinical Trials: A Meta-Analysis of Longitudinal Studies

Abstract

Background

Liver biopsy and virological end points are standard references for assessing the effect of viral hepatitis treatments. We aimed to review evidence-based published data of biomarkers that have been validated as non-invasive alternatives to biopsy as end points for HBV and HCV infection trials.

Methods

Studies were included if there were at least two repeated estimates of fibrosis per patient using biomarkers with at least two studies and a control group. Meta-analysis of the percentage of fibrosis progression per year (pFPy) was performed.

Results

Two biomarkers were included, FibroTest® and liver stiffness measurement (LSM; FibroScan®). A total of 1,413 patients with chronic hepatitis C (11 populations) and 772 with chronic hepatitis B (6 populations) were analysed. In a comparison of HCV patients with controls, the FibroTest® pFPy was -18% (95% confidence interval [CI] -23– -14; P<0.001) in treated patients and the LSM pFPy was -15% (95% CI -28– -1; P=0.01), both with differences according to virological responses. In HBV patients, there was a significant decrease of the pFPy only in patients with baseline advanced fibrosis (mean difference -5% [95% CI -10– -0.1]; P=0.02). In patients with advanced fibrosis, stratified by virological response, there were similar differences between pFPy estimated either using FibroTest® or biopsy, both in HCV and HBV infections. Repeated LSM in HBV patients had an early variability related to necroinflammatory activity.

Conclusions

In patients with chronic hepatitis C and B, the treatment effect on fibrosis progression rate was similarly estimated using FibroTest® or biopsy. The same concordance was observed for FibroScan® but with a possible overestimation of the fibrosis regression during the first weeks of treatment.

References

Lavanchy

The global burden of hepatitis C.

Liver Int 2009; 29 Suppl 1: 74–81.

Poynard

, Yuen

M.F.

, Ratziu

Viral hepatitis C.

Lancet 2003; 362: 2095–2100.

Lavanchy

Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention.

J Clin Virol 2005; 34 Suppl 1: S1–S3.

Lai

C.L.

, Ratziu

, Yuen

M.F.

, Poynard

Viral hepatitis B.

Lancet 2003; 362: 2089–2094.

Schuppan

, Afdhal

N.H.

Liver cirrhosis.

Lancet 2008; 371: 838–851.

Manns

M.P.

, McHutchison

J.G.

, Gordon

S.C.

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Lancet 2001; 358: 958–965.

Fried

M.W.

, Shiffman

M.L.

, Reddy

K.R.

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

N Engl J Med 2002; 347: 975–982.

Lai

C.L.

, Shouval

, Lok

A.S.

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

N Engl J Med 2006; 354: 1011–1020.

Chang

T.T.

, Gish

R.G.

, de Man

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

N Engl J Med 2006; 354: 1001–1010.

10.

Marcellin

, Heathcote

E.J.

, Buti

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

N Engl J Med 2008; 359: 2442–2455.

11.

Manning

D.S.

, Afdhal

N.H.

Diagnosis and quantitation of fibrosis.

Gastroenterology 2008; 134: 1670–1681.

12.

Poynard

, Morra

, Ingiliz

Biomarkers of liver fibrosis.

Adv Clin Chem 2008; 46: 131–152.

13.

Castera

, Denis

, Babany

, Roudot-Thoraval

Evolving practices of non-invasive markers of liver fibrosis in patients with chronic hepatitis C in France: time for new guidelines?

J Hepatol 2007; 46: 528–529.

14.

McHutchison

, Poynard

, Afdhal

, International Fibrosis Group Meeting Participants. Fibrosis as an end point for clinical trials in liver disease: a report of the international fibrosis group. Clin Gastroenterol Hepatol 2006; 4: 1214–1220.

15.

La Haute Autorité de Santé (HAS; France). The HAS recommendations for the management of the chronic hepatitis C using non-invasive biomarkers. (Updated December 2008. Accessed June 2010.) Available from http://www.has-sante.fr/portail/plugins/ModuleXitiKLEE/types/FileDocument/doXiti.jsp?id=c_783807.

16.

Fontaine

, Petitprez

, Roudot-Thoraval

Guidelines for the diagnosis of uncomplicated cirrhosis.

Gastroenterol Clin Biol 2007; 31: 504–509.

17.

European Medicines Agency. Guideline on the clinical evaluation of direct acting antiviral agents intended for treatment of chronic hepatitis C. (Updated May 2008. Accessed June 2010.) Available from www.ema.europa.eu/pdfs/human/ewp/617203en.pdf.

18.

Poynard

, Morra

, Halfon

Meta-analyses of FibroTest diagnostic value in chronic liver disease.

BMC Gastroenterol 2007; 7: 40.

19.

Halfon

, Munteanu

, Poynard

FibroTest-ActiTest as a non-invasive marker of liver fibrosis.

Gastroenterol Clin Biol 2008; 32: 22–38.

20.

Shaheen

A.A.

, Myers

R.P.

Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review.

Hepatology 2007; 46: 912–921.

21.

Shaheen

A.A.

, Wan

A.F.

, Myers

R.P.

FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy.

Am J Gastroenterol 2007; 102: 2589–2600.

22.

Poynard

, Muntenau

, Morra

Methodological aspects for the interpretation of liver fibrosis non-invasive biomarkers: a 2008 update.

Gastroenterol Clin Biol 2008; 32: 8–21.

23.

Friedrich-Rust

, Ong

M.F.

, Martens

Performance of transient elastography for the staging of liver fibrosis: a meta-analysis.

Gastroenterology 2008; 134: 960–974.

24.

Poynard

, Massard

, Rudler

Impact of interferon-alpha treatment on liver fibrosis in patients with chronic hepatitis B: an overview of published trials.

Gastroenterol Clin Biol 2009; 33: 916–922.

25.

Ghany

M.G.

, Strader

D.B.

, Thomas

D.L.

, Seeff

L.B.

, American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335–1374.

26.

Tong

M.J.

, Hsien

, Hsu

, Sun

H.E.

, Blatt

L.M.

Treatment recommendations for chronic hepatitis B: an evaluation of current guidelines based on a natural history study in the United States.

Hepatology 2008; 48: 1070–1078.

27.

Poynard

, Mathurin

, Lai

C.L.

A comparison of fibrosis progression in chronic liver diseases.

J Hepatol 2003; 38: 257–265.

28.

Hintze

J.L.

NCSS 2007 User Guide. Kaysville: Number Cruncher Statistical Systems software NCSS 2007; pp. 200.

29.

Ngo

, Munteanu

, Messous

A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C.

Clin Chem 2006; 52: 1887–1896.

30.

Vergniol

, Foucher

, Castéra

Changes of non-invasive markers and FibroScan values during HCV treatment.

J Viral Hepat 2009; 16: 132–140.

31.

Ogawa

, Furusyo

, Toyoda

, Takeoka

, Maeda

, Hayashi

The longitudinal quantitative assessment by transient elastography of chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin.

Antiviral Res 2009; 83: 127–134.

32.

Poynard

, Imbert-Bismut

, Ratziu

Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial.

J Viral Hepat 2002; 9: 128–133.

33.

Poynard

, McHutchison

, Manns

, Myers

R.P.

, Albrecht

Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin.

Hepatology 2003; 38: 481–492.

34.

d'Arondel

, Munteanu

, Moussalli

A prospective assessment of an ‘a la carte’ regimen of PEG-interferon alpha2b and ribavirin combination in patients with chronic hepatitis C using biochemical markers.

J Viral Hepat 2006; 13: 182–189.

35.

Patel

, Benhamou

, Yoshida

E.M.

An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C.

J Viral Hepat 2009; 16: 178–186.

36.

Halfon

, Carrat

, Bédossa

Effect of antiviral treatment on serum markers of liver fibrosis in HIV-hepatitis C virus-coinfected patients: the Fibrovic 2 Study – ANRS HC02.

Antivir Ther 2009; 14: 211–219.

37.

Ngo

, Benhamou

, Thibault

An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral load.

PLoS ONE 2008; 3: e2573.

38.

Poynard

, Ngo

, Marcellin

Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest-ActiTest) in patients infected by hepatitis B virus.

J Viral Hepat 2009; 16: 203–213.

39.

Poynard

, Zoulim

, Ratziu

Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection.

Am J Gastroenterol 2005; 100: 1970–1980.

40.

Oliveri

, Coco

, Ciccorossi

Liver stiffness in the hepatitis B virus carrier: a non-invasive marker of liver disease influenced by the pattern of transaminases.

World J Gastroenterol 2008; 14: 6154–6162.

41.

Poynard

, Bedossa

, Opolon

Natural history of liver fibrosis progression in patients with chronic hepatitis C.

Lancet 1997; 349: 825–832.

42.

Thein

H.H.

, Yi

, Dore

G.J.

, Krahn

M.D.

Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression.

Hepatology 2008; 48: 418–431.

43.

Davis

G.L.

, Alter

M.J.

, El-Serag

, Poynard

, Jennings

L.W.

Aging of the hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression.

Gastroenterology 2010; 138: 513–521.

44.

Vispo

, Barreiro

, Del Valle

Overestimation of liver fibrosis staging using transient elastography in patients with chronic hepatitis C and significant liver inflammation.

Antivir Ther 2009; 14: 187–193.

45.

Morra

, Lebray

, Ingiliz

FibroTest has better diagnostic and prognostic values than the aspartate aminotransferase-to-platelet ratio index in patients with chronic hepatitis C.

Hepatology 2008; 47: 353–354.

46.

Al-Mohri

, Murphy

, Lu

, Lalonde

R.G.

, Klein

M.B.

Evaluating liver fibrosis progression and the impact of antiretroviral therapy in HIV and hepatitis C coinfection using a noninvasive marker.

J Acquir Immune Defic Syndr 2007; 44: 463–469.

47.

Gebo

K.A.

, Herlong

H.F.

, Torbenson

M.S.

Role of liver biopsy in management of chronic hepatitis C: a systematic review.

Hepatology 2002; 36: S161–S172.

48.

Fontana

R.J.

, Bonkovsky

H.L.

, Naishadham

Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis.

Clin Gastroenterol Hepatol 2009; 7: 219–226.

49.

Poynard

, Schiff

E.R.

, Terg

FibroTest (Ft) baseline value is an independent predictor of early (EVR) and sustained virological response (SVR) in non-responders patients re-treated with pegylated interferon alfa-2B (PEG-2B) and ribavirin in EPIC³.

J Hepatol 2009; 50 Suppl 1: S156.

50.

Di Bisceglie

A.M.

, Shiffman

M.L.

, Everson

G.T.

Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon.

N Engl J Med 2008; 359: 2429–2441.

51.

Poynard

, Ratziu

Prolonged therapy for hepatitis C with low-dose peginterferon.

N Engl J Med 2009; 360: 1152. Author reply 1152–1153.